NanoString Blog
Category: Q&A
Grants Q&A Transplant
Molecular Signatures of Antibody-Mediated Rejection and Graft Outcome After Kidney Transplantation. Q&A with Dr. Dela Golshayan, M.D., Ph.D.
When Newsweek Magazine rates you the 9th best Hospital in the World, you know you are doing something remarkable! Located in Lausanne, Switzerland, Lausanne University Hospital (CHUV) sits on Lake Geneva…
Grants Q&A
Grant Writing for Dummies: Tips & Tricks for Success
Grant writing is an integral part of the life of a scientist and not an easy task. Despite multiple opportunities to obtain funding, the competition is fierce. To help our…
Digital Spatial Profiling Q&A Services and Core Labs
Excellence, Cooperation, and Passion Come Together to Serve the Scientific Community: Q&A with Dr. Peter O’Toole, University of York
Dr. Peter O’Toole, Ph.D., is the director of the Bioscience Technology Facility at the University of York in England, where he established and still leads the Imaging and Cytometry Laboratory, one of the…
Oncology Q&A
Statistically Significant Results without the Headache. Q&A with Sarah Church, Ph.D., Senior Scientist at NanoString.
Talking to Sarah, whether during social gatherings or within the office walls, is always a pleasure. Dr. Church is a Senior Scientist at NanoString and one of the warmest people…
Q&A Services and Core Labs
Spotlight on a CRO: Interview with the Team of Scientists behind NeoGenomics Pharma Services.
NeoGenomics is a cancer diagnostics and pharma services company serving pharmaceutical companies and academic centers. They specialize in diagnostic, prognostic and predictive testing using the most innovative technologies. The company…
Oncology Q&A
Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.
Dr. Nina Radosevic-Robin, MD, is a Board-Certified Surgical/Molecular Pathologist at Centre Jean Perrin, a Sr. Scientist within the Unit 1240 of French National Institute for Medical Research (INSERM), and a…
Immunology Oncology Q&A
Why is Spatial Transcriptomics Critical to Studying Sarcomas? Q&A with Dr. Troy McEachron, Ph.D
“Whereas the EWS specimens tended to have very simple genomes, the osteosarcoma specimens looked like a hand grenade had gone off in the genome. These were the most fragmented and…
Grants Q&A Transplant
Solid Organ Transplantation and the Immunology of Rejection. Q&A with GeoMx® Digital Spatial Profiler Grant Winner Dr. Fadi Issa
“Cancer immunotherapy and transplantation are basically the same field; one’s just the flip side of the other”. Dr. Fadi Issa Have you ever been to Oxford? Situated in the gorgeous…
Grants Q&A Transplant
Searching for New Biomarkers to Prevent Organ Transplant Rejection. Q&A with HOT Panel Grant Winner Dr. Evan Farkash
Bob’s first question to me was: “How much do you want to learn about kidney pathology?” My response was that I wanted to learn as much as I could, and…
Q&A Services and Core Labs
Spotlight on a CRO. Q&A with Dr. Edward J. Weinstein, Ph.D., CEO and co-founder of Canopy BioSciences.
There is a lot to love in the beautiful city of St. Louis: from the quiet neighborhoods permeated with old world charm to the picturesque streets reminiscent of Paris “petites…
Grants Q&A Transplant
Q&A with Paola Cassoni, M.D., Ph.D. on Understanding the Pathway to Organ Rejection.
Turin is a lovely Italian city situated between the western and northern borders of Italy by the Alps, looking east at the Monferrato Hills. The Mole Antonelliana, the proud city…
Digital Spatial Profiling Q&A
Q&A with Dr. Aubrey Thompson, Ph.D.: The GeoMx® Digital Spatial Profiler is Turning the Tables on Breast Cancer
E. Aubrey Thompson, Ph.D is a Professor in the Department of Cancer Biology at the Mayo Clinic in Jacksonville, FL. His research focuses on breast cancer and using genomic and…